Today was a good day to be teaching investments. My student managed investment fund class was a bit shell shocked at losing 3 1/2 % of the fund's value in one day (we meet on a MWF schedule, so there wasn't class on Tuesday). .And 100% of our 20+ positions in the fund ended in the red for the day (hence the title of this post). So, there was a lot of discussion about the various stories explaining the drop (Shanghai, bad economic news, and the ever-popular "Greenspan said we're due for a recession").
The biggest positive of this experience is that it has sharpened their focus on the "downside" of being in the market. If you're going to be in the market, you have to see a major correction at some point, and it's better to see it earlier than later (and it's even better if you can experience it with some else's money). We spent a lot of time discussing some positions we plan on exiting and whether or not to sell now, wait and see, or put in stop losses. Of course, I won't tell you what they decided.
But on the good side, the fund has clawed back almost 8/10 of a percent today. It's still not great, but it is an improvement over yesterday's results.
update: It was interesting teaching CFA last night - I got to talk with a couple of equity traders. One had been at it for about 7 years, and had a lot of relatively young guys in her group (almost all had started post 9-11). She enjoyed the panic they expressed since they'd never experience a correction like this. So it's not just my students.
The Private Equity and Academic Research Link Dump
It's been a while since I did a proper link dump, so it's time to clean out the buffer. I teach CFA again tonight, so I have to leave shortly and prepare. But in the meanwhile, here are some links for your reading pleasure. As usual, they're heavy on Private Equity and Academic research:
That should keep ya busy. Time to catch my train.
Hedge Fund and Private Equity
Mark Hulbert discusses the effectiveness of hedge fund activism in the New York Times (online subscription required).
In a related piece, Equity Private at Going Private is blogging on the relations between Private Equity and Shareholder Activists. The Cliff Notes version (but definitely read the whole thing) is that the two groups have a lot of overlap, but also provide different mechanisms for resolving agency problems.
Texas Pacific Group's founding partner David Bonderman made some opening comments at today’s Super Return 2007 private equity conference in Frankfurt
Academic Research
Green, Jegadeesh, and Tang (three finance profs at Emory University) examine the performance of men vs. women analysts in Gender and Job Performance: Evidence from Wall Street. Dang - another piece I wish I'd written.
Fama and French have just written another interesting piece on the size and market-to-book effects titled "Migration. They study ..."how migration of firms across size and value portfolios contributes to the size and value premiums in average stock returns. The size premium is almost entirely due to the small stocks that earn extreme positive returns and as a result become big stocks. The value premium has three sources: (i) value stocks that improve in type either because they are acquired by other firms or because they earn high returns and so migrate to a neutral or growth portfolio; (ii) growth stocks that earn low returns and as a result move to a neutral or value portfolio; and (iii) slightly higher returns on value stocks that remain in the same portfolio compared to growth stocks that do not migrate." HT: Jim Mahar at Financeprofessor.com
Finally, Boudoukh, Michaely, Richardson, and Roberts have a forthcoming Journal of Finance piece titled "On the Importance of Payout Yield". They find that "...the widely documented decline in the predictive power of dividends for excess stock returns is due largely to the omission of alternative channels by which firms distribute and receive cash from shareholders. Statistically and economically significant predictability is found in the time series when payout (dividends plus repurchases) and net payout (dividends plus repurchases minus equity issuances) yields are used instead of dividend yield."
That should keep ya busy. Time to catch my train.
Advice to New Faculty
Greg Mankiw's Blog is a must read for aspiring economists. He just posted some spot-on "Advice for Junior Faculty" the best pieces IMO are:
- Focus on getting papers published - everything else is secondary. And don't be a perfectionist. Get the thing out the door and onto a referee's desk.
- It pays to be a good teacher and a good citizen in your department, but it won't get you tenure
- Attend conferences and give seminars at schools to publicize your work and yourself.
- Give each of your papers a shot or two at the top journals, such as the AER, JPE, or QJE.
- Do not get discouraged by rejection.
- Schedule time for writing every day (preferably first thing). It doesn't have to be a lot - just commit to 30 minutes every day. Other things will creep in and steal your time So do it first.
- Read Boice's Advice For New Faculty Members. It's short, cheap, and well worth the read. And it'll get you started on your careers with good habits.
Hopefully The Last In a Series
I hope this doesn't jinx things, but the latest round of Zithromax seems to have had a good effect on the pneumonia. Good thing, 'cuz I have multiple coauthors clamoring for attention. So with luck, I can get back to being somewhat productive.
Today's an exam day, so it's an easy one for me. Unfortunately, the grading comes later, which is my least favorite part of the job (that, and committee meetings). But the rest of the day is carved out for working on a rewrite of a 45 page paper. Woo hoo!
Hopefully, this will be the last of the "I'm still sick" posts for a while.
Today's an exam day, so it's an easy one for me. Unfortunately, the grading comes later, which is my least favorite part of the job (that, and committee meetings). But the rest of the day is carved out for working on a rewrite of a 45 page paper. Woo hoo!
Hopefully, this will be the last of the "I'm still sick" posts for a while.
You can pick your frends, you can pick your nose, and you can PIK your bonds
Wednesday's WSJ had a very interesting piece on "PIK " or "Payment In Kind" bonds, titled "What's Aiding Buyout Boom: Toggle Notes." It's perfect to bring into the classroom if you're teaching about capital structure, M&A, financial engineering, or derivatives.
For the unitiated, a payment in kind toggle (I'll just call them PIK bonds from here on out) bond gives the issuer the option of not paying coupon payments. If they exercise the option (i.e. "flip the toggle"), the liability for the missed payments payments accrues (at an interest rate higher than the coupon rate) and is repaid at maturity. The article notes the recent PIK bond issued in the takeover of Neiman-Marcus - it has a 9% coupon, and a 75 basis point higher (i.e. 9.75%) rate on "toggled" payments.
In a Miller and Modigliani 1958 world, there aren't any costs to financial distress. In the real world, there are serious consequences to missing a coupon payment. Even more, actions taken to avoid this eventuality can cause distortions in firms investment and disclosure activities. So PIK bonds are a creative financial engineering solution to the problem.
It's not surprising that PIK toggle bonds have been seen mostly in the PE world. These deals end up highly leveraged. So, there's a significant risk that a target firm could get driven under by an external shock completely out of their control (the article uses 9-11 as an example). And the "insurance" seems pretty cheap at 75 basis points.
It's also interesting in terms of how you'd price the option. Since the option would be exercised if the firm was underwater on its debt payments, it's actually an option on the cash flows of the firm rather than on a traded security. Since the issuing firm has a much better feel for those numbers than the credit markets do, there should be a significant adverse selection problem with these securities. My guess is that the insurance (the 75 b.p. spread on the toggled payments) will turn out to be way too low.
There's some good commentary on the topic from the usual suspects: Abnormal Returns has a nice roundup of PE/credit related posts, and Going Private analyzes the effects of PIK financing on the PE firms equity returns.
And if you have no clue about what a PE firm is and does, here's a pretty good video primer on Private Equity from CNNMoney.com
For the unitiated, a payment in kind toggle (I'll just call them PIK bonds from here on out) bond gives the issuer the option of not paying coupon payments. If they exercise the option (i.e. "flip the toggle"), the liability for the missed payments payments accrues (at an interest rate higher than the coupon rate) and is repaid at maturity. The article notes the recent PIK bond issued in the takeover of Neiman-Marcus - it has a 9% coupon, and a 75 basis point higher (i.e. 9.75%) rate on "toggled" payments.
In a Miller and Modigliani 1958 world, there aren't any costs to financial distress. In the real world, there are serious consequences to missing a coupon payment. Even more, actions taken to avoid this eventuality can cause distortions in firms investment and disclosure activities. So PIK bonds are a creative financial engineering solution to the problem.
It's not surprising that PIK toggle bonds have been seen mostly in the PE world. These deals end up highly leveraged. So, there's a significant risk that a target firm could get driven under by an external shock completely out of their control (the article uses 9-11 as an example). And the "insurance" seems pretty cheap at 75 basis points.
It's also interesting in terms of how you'd price the option. Since the option would be exercised if the firm was underwater on its debt payments, it's actually an option on the cash flows of the firm rather than on a traded security. Since the issuing firm has a much better feel for those numbers than the credit markets do, there should be a significant adverse selection problem with these securities. My guess is that the insurance (the 75 b.p. spread on the toggled payments) will turn out to be way too low.
There's some good commentary on the topic from the usual suspects: Abnormal Returns has a nice roundup of PE/credit related posts, and Going Private analyzes the effects of PIK financing on the PE firms equity returns.
And if you have no clue about what a PE firm is and does, here's a pretty good video primer on Private Equity from CNNMoney.com
Still On The Mend
Just Damn.
At the beginning of the week, I still had mild fevers (about 101.5-102), coughing fits, and lots of wonderful stuff coming up from my lungs. So, I went back to the Doc. I told her that I'm really not stalking her (hey - she's young and cute, so at least there's some payoff to these visits), but that I was hoping that it's like a coffee shop where every tenth visit is free.
I finally had an X-Ray done, and there's a significant amount of goop (at least, I think that's the technical term for it) in my lower lungs. The actual diagnosis? It's either viral pneumonia that hasn't resolved yet or bacterial pneumonia that the first does of antibiotics (Levaquin) didn't quite knock out. So, it's on to a second round of antibiotics (Zithromax this time). If it's the first case, the antibiotics will keep anything else from growing there, and if it's the second, this additional dose should do the trick.
Doc said that Zithromax has the unfortunate downside of causing "some lower GI effects" (i.e. diarrhea). I'm hoping it'll cancel out the constipation caused by the codeine based cough suppressant I'm taking (sorry - that's a clear case of WAY too much information). So with luck, they'll cancel each other out. Yeah, right.
It's been three days since I started the new regimen, and I felt much better this morning. With luck, I'll be back to my old self. I was hoping for better, but I guess I can live with that.
At the beginning of the week, I still had mild fevers (about 101.5-102), coughing fits, and lots of wonderful stuff coming up from my lungs. So, I went back to the Doc. I told her that I'm really not stalking her (hey - she's young and cute, so at least there's some payoff to these visits), but that I was hoping that it's like a coffee shop where every tenth visit is free.
I finally had an X-Ray done, and there's a significant amount of goop (at least, I think that's the technical term for it) in my lower lungs. The actual diagnosis? It's either viral pneumonia that hasn't resolved yet or bacterial pneumonia that the first does of antibiotics (Levaquin) didn't quite knock out. So, it's on to a second round of antibiotics (Zithromax this time). If it's the first case, the antibiotics will keep anything else from growing there, and if it's the second, this additional dose should do the trick.
Doc said that Zithromax has the unfortunate downside of causing "some lower GI effects" (i.e. diarrhea). I'm hoping it'll cancel out the constipation caused by the codeine based cough suppressant I'm taking (sorry - that's a clear case of WAY too much information). So with luck, they'll cancel each other out. Yeah, right.
It's been three days since I started the new regimen, and I felt much better this morning. With luck, I'll be back to my old self. I was hoping for better, but I guess I can live with that.
Two Nobel Winners For The Price of One
Today's Wall Street Journal has an interview of Nobel Prize Winner Thomas Schelling by his student Michale Spence (another Nobel winner). It's a must read - Schelling and Spence discuss nuclear deterrence and other weighty topics.
Subscribe to:
Posts (Atom)